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ABSTRAK 
KAJIAN AWAL EKPRESI GEN NEUREGULIN 1 DALAM PESAKIT 
SKIZOFRENIA YANG MENGAMBIL PALIPERIDONE DI KALANGAN 
RAKYAT MALAYSIA DI PUSAT PERUBATAN UNIVERSITI MALAYA 
(UMMC) 
LATAR BELAKANG: Polimorfisme gen Neuregulin 1(NRG 1) telah dipertimbangkan 
sebagai gen yang menyebabkan penyakit Skizofrenia . Ini terbukti dalam pelbagai kajian 
yang dijalankan dalam beberapa populasi Eropah dan Cina yang menunjukkan kaitan 
yang kuat diantara gen NRG 1 dan Skizofrenia. Terdapat banyak kajian yang berkaitan 
di seluruh dunia dan di rantau Asia tetapi tidak di Malaysia yang terdiri daripada 3 kaum 
utama. Oleh itu, adalah penting untuk memahami kelebihan mengukur ekpresi gen 
NRG 1 yang memainkan peranan penting sebagai faktor risiko untuk penyakit 
Skizofrenia dan ini menyarankan kemungkinan gen NRG 1 mempunyai potensi sebagai 
‗biomarker‘ untuk penyakit Skizofrenia. 
OBJEKTIF:Pesakit Skizofrenia yang menerima rawatan paliperidone akan diukur 
untuk ekspresi gen NRG 1. Tujuan kajian ini adalah untuk menyiasat ekpresi gen NRG 
1 dalam pesakit Skizofrenia dan kaitan diantara ekspresi gen NRG 1 dengan 
simtomatologi.  
 
METODOLOGI: Kajian keratan rentas ini dijalankan di Pusat Perubatan Universiti 
Malaya (PPUM). Subjek terdiri daripada mereka yang menghadiri perkhidmatan 
psikiatri dan perubatan di UMMC dari Februari 2011 hingga November 2011 (10 
bulan). Tahap ekpresi gen NRG 1 diukur bagi semua indidvidu yang mengambil 
rawatan Paliperidone dan kawalan sihat . Maklumat mengenai faktor-faktor sosio-
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demografi (umur,status perkahwinan ,status pekerjaan) dan 
klinikal yang berkaitan ,(sejarah penyakit mental dalam keluarga,tempoh berpenyakit 
mental dan Psikopatologi dinilai menggunakan Mini International Neuropsychiatric 
Interview (M.I.N.I) Positive And Negative Syndrome Scale  (PANSS) dan kesan-kesan 
sampingan dinilai menggunakan Barnes Akathisia Rating Scale (BARS) dikumpulkan. 
 
KEPUTUSAN:  Sejumlah 20 pesakit Skizofrenia dan 15 kawalan sihat telah 
dimasukkan ke dalam kajian ini. Di kalangan pesakit skizofrenia majoriti adalah bujang 
(80%) , tidak bekerja (70%) dan mempunyai sejarah keluarga penyakit skizofrenia ( 
55%). Purata ukuran ekspresi gen NRG 1 dalam 20 pesakit Skizofrenia kami ialah 0.405 
(SD= 0.491). Tiada faktor yang signifikan berkaitan dengan ekspresi gen NRG 1. Tiada 
faktor signifikan yang berkaitan dengan ekspresi gen NRG 1 dengan psikopatologi dan 
kawalan sihat. 
 
KESIMPULAN: Purata ukuran ekspressi gen NRG 1 di kalangan rakyat Malaysia 
adalah 0.405 (SD= 0.491). Pesakit yang mempunyai markah PANSS yang rendah 
mempunyai ukuran ekspresi gen NRG 1 yang rendah (mean =0.304) berbanding dengan 
pesakit yang mempunyai markah PANSS yang tinggi (mean = 0.524) dan kawalan 
sihat.Keputusan ini menyarankan bahawa ada perubahan ekspresi gen NRG 1 dalam 
pesakit skizofrenia yang mengambil paliperidone di kalangan rakyat Malaysia. Pada 
masa akan datang , satu kajian prospektif dengan saiz sampel yang lebih besar 
diperlukan untuk kajian yang lebih mendalam untuk topik ini. 
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ABSTRACT 
A PRELIMINARY STUDY OF NEUREGULIN 1 GENE EXPRESSION IN 
SCHIZOPHRENIA PATIENTS ON PALIPERIDONE IN A MALAYSIAN 
POPULATION IN UNIVERSITY MALAYA MEDICAL CENTRE (UMMC) 
 
BACKGROUND: The Neuregulin 1gene (NRG 1) polymorphism has been considered 
as a susceptibility gene for Schizophrenia. This is evident from studies done in several 
European and Chinese populations that suggesting a strong association between NRG 1 
gene and Schizophrenia. There are numerous related studies worldwide and in Asian 
region but not in Malaysia that consists of 3 major races. Therefore, it is important for 
us to understand the reason for measuring NRG 1 gene expression given the importance 
of the gene as a risk factor for Schizophrenia, suggesting that NRG1 may have the 
potential as a biomarker for schizophrenia.  
OBJECTIVE: Schizophrenic patients on paliperidone treatment to be measured for 
NRG 1 gene expression. The aim of this study is to investigate NRG 1 gene expression 
in Schizophrenia subjects and the association of NRG 1 expression level with 
symptomatology. 
 
METHODOLOGY: This was a cross sectional study conducted in University Malaya 
Medical Centre (UMMC). Subjects were recruited from those attending the psychiatry 
and medical services in UMMC from February 2011 until November 2011 (10 months). 
The NRG 1 gene expression was measured for subjects on paliperidone treatment and in 
the control group. The information on socio-demographic (age, marital status, 
employment status) and clinical factors (family history of mental illness, duration of 
 xx 
 
illness and psychopathology using Mini International Neuropsychiatric Interview 
(M.I.N.I) Positive And Negative Syndrome Scale  (PANSS) and side effects using 
Barnes Akathisia Rating Scale (BARS) were collected. 
 
RESULT: A total of 20 Schizophrenia subjects and 15 healthy controls were recruited 
for this study. Among the 20 schizophrenia subjects majority were single (80%), 
unemployed (70%) and have family history of schizophrenia (55%). The average NRG 
1 gene expression level in our 20 schizophrenia patients was 0.405 (SD= 0.491) and in 
the control group was 0.435 (SD= 0.273). No factors were found to be significantly 
associated with NRG 1 gene expression level. There was no significant association 
between NRG 1 gene expression level and psychopathology. 
 
CONCLUSION: The average NRG 1 gene expression level among Malaysians was 
0.405 (SD= 0.491).Those with low PANSS score had lower NRG 1 levels (mean 
=0.304) compared to those with high PANSS score (mean = 0.524) and control group. 
This suggests that there is altered NRG 1 expression in Schizophrenic patients on 
Paliperidone in Malaysian population. In the future, a prospective study with larger 
sample size is needed to look further into this topic. 
 
 1 
 
CHAPTER 1: INTRODUCTION  
1.1 BACKGROUND AND HISTORICAL PROSPECTIVE  
Each individual responds differently to treatment regimes; this is also true of mental illness 
sufferers. In schizophrenia, antipsychotics are the mainstay of treatment for psychotic 
symptoms (Arranz and de Leon 2007). Individuals respond in numerous ways to treatment; 
be it a favourable outcome, an adverse event or no response. There are multiple factors 
involved in determining a patient‘s response to treatment : environmental factors, adherence 
, severity of illness, co-morbid medical conditions , type of drug prescribed ( atypical or 
conventional, generic or original compound ), drug – drug interaction , age and of course, 
the individual‘s genetic profile itself plays a role (Aitchison 2002). In order to improve 
patient care one of the emerging fields in psychiatry is pharmacogenomics and 
pharmacogenetics. 
 
Why are these fields important? Pharmacogenomics and pharmacogenetic profiling will 
enable psychiatrists to individualize treatment and minimize exposure to multiple drugs. 
Pharmacogenetics was coined by Vogel in 1950s to define inherited variability in response 
to drug treatment. Pharmacogenetics is concerned with finding identifying or investigating 
candidate genes that can cause individuals to have differences in drug effect (Arranz and de 
Leon 2007). The genes are selected based on their drug targets or coding for metabolic 
enzymes.(Arranz 2003).These differences would affect therapeutic efficacy, effectiveness 
and adverse reactions. In 1995, the Human Genome Project was initiated; this mega project 
later on helped pharmacogenetics to evolve into pharmacogenomics . Pharmacogenomics 
uses a hypothesis based approach that studies genome factors and drug response at cellular, 
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tissue , individual , group level (Aitchison 2002). Information regarding functional activity 
and differential gene expression in areas related to the aetiology of the disease is another 
approach use in the field of pharmacogenomics (Arranz 2003).  
 
The search includes genes determining disease susceptibility and those causing individual 
variations in drug response, based on the knowledge derived from the Human Genome 
Project (Aitchison 2002).Both of these fields‘ aim to guide pharmacotherapy and improve 
outcome by providing individualized treatment. In the future both fields will help discover 
novel drugs and accelerate clinical improvement. Pharmacogenomics and 
pharmacogenetics have great promise particularly in psychiatry as there is lack of biological 
based treatment guidelines. As of now, there are no diagnostic biomarkers in psychiatry 
.Individual variability in drug response can often be understood as a combination of factors 
affecting the pharmacokinetic and pharmacodynamic effects of drugs. This is where 
pharmacogenomics studies are helpful and candidate genes include polymorphic drug-
metabolizing enzymes, drug transporters and polymorphic drug targets that affect disease-
related pathway (Tsapakis, Basu et al. 2004).  
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1.2 .GLOBAL BURDEN OF MENTAL ILLNESS 
Mental illness is the ‘plague‘ of the 21st century population that is fast becoming a growing 
concern globally. Schizophrenia is a chronic illness that debilitates an individual and 
remains with them throughout their life. Schizophrenia is the most frequently encountered 
psychotic illness. The lifetime prevalence of schizophrenia is approximately 1% and the 
point prevalence is around 0.5%. In the Global Burden of Disease 2000 study it was found 
that schizophrenia accounted for 2.8% of the years lost to death (YLD) and 1.1% of the 
Disability Adjusted Life Year DALYs (Michaud, Murray et al. 2001). The Global Disease 
Burden of Disease Study developed new ways to measure health status that accounted for 
disability along with the number of deaths and the impact of premature death. To quantify 
the burden of disease the researchers came up with DALY (disability adjusted life year). 
The DALY is a summary measure of population health that combines in a single indicator 
years of life lost from premature death and years of life lived with disabilities. One DALY 
can be thought of as one lost year of ‗healthy‘ life. In the Version 1 estimates for the Global 
Burden of Disease 2000 study, published in the World Health Report 2001 (2)(World 
Health Organisation), schizophrenia is the 7th leading cause of YLDs at global level, 
accounting for 2.8% of total global YLDs. Hence, this shows that mental illness has a 
significant and detrimental impact on social health, on economy incurring direct and 
indirect costs to individual, families and government. 
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1.3. LOCAL BURDEN OF MENTAL ILLNESS – MALAYSIAN PERSPECTIVE  
The third national health and morbidity survey was conducted in 2006 on 36,519 
respondents aged 16 years and above using General Health Questionnaire (GHQ 28) and 
found overall unadjusted prevalence for mental disorders was 11.2 % (Health 2006 ) . 
Mental illness is considered to be a non communicable and chronic disease, in Malaysia, 
chronic diseases accounted for 71% of all deaths in 2002 (WHO 2002).In 2005 , the 
Malaysia burden of Disease and Injury Study was conducted and found that the total  
burden of disability in Malaysia population in year 2000 amounts to 1.1 million years 
(Yusoff AF 2005). The National Mental Health Registry (NMHR) reported that 70% of 
patients were never employed or unemployed at the time of registration. Furthermore, the 
demographic profile shows that the majority of patients with schizophrenia in Malaysia are 
in the productive age of 20-40 years(Aziz, Salina et al. 2008). In view of all the findings it 
reflected the impact of mental illness in developing countries such as Malaysia and the 
burden would continue to increase with the increase in migration an urbanization of its 
population. 
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1.4 LITERATURE REVIEW  
1.4.1 SCHIZOPHRENIA SYPTOMATOLOGY  
There was much debate regarding naming this illness, initially it was known as demence 
precoce by Morel, Hebephrenia by Hecker and Catatonia by Kahlbaum. The term 
schizophrenia came about at the end of 19th century and it was coined by a Swiss 
psychiatrist Eugene Bleuler which is still in use until now (Michael 2000). Schizophrenia is 
a mental illness that is distressful to both patient and physician. For the physician the 
diagnosis can be made difficult at times, as the presentation may not be as straight forward 
as it seems. To diagnose the symptoms must be present for a significant portion of time 
during a 1-month period; during which the patient experiences: Two (or more) of the 
following DSM IV TR criteria for Schizophrenia (Association. 2000): 
 Delusions  
 Hallucinations  
 Disorganized speech 
 Grossly disorganized or catatonic behavior or 
 Negative symptoms, such as affective flattening, alogia, or avolition .  
These symptoms burden the patients until they are unable to function socially and 
occupationally (Association. 2000) . Affective symptoms can also manifest in 
schizophrenia either as depression or anxiety. The more common symptom is depression 
whereby it can be the core feature of schizophrenia , occur in prodromal phase of illness , it 
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is the prominent symptom in acute or chronic episodes or post psychotic depression ( early 
or late onset ) (Mulholland and Cooper 2000) . The other symptoms that are seen in 
schizophrenia are motor symptoms, cognitive symptoms , lack of insight , minor physical 
anomalies and neurological signs ( soft or hard ) (Tandon, Nasrallah et al. 2009).  
People afflicted with schizophrenia are at higher risk of having intellectual impairment 
approximately 3-5% are affected (Morgan, Leonard et al. 2008) , substance abuse estimated 
at 47 % , affective disorder most commonly depression estimated at 50 % and anxiety 
disorders. The symptoms for anxiety and depression are relatively common throughout the 
course of illness, with an estimated prevalence of 15% for panic disorder, 29% for post 
traumatic stress disorder, and 23% for obsessive-compulsive disorder  (Buckley, Miller et 
al. 2009). 
The mortality rate in individual with schizophrenia is increased and this can be due to 
several factors (Capasso, Lineberry et al. 2008) .Two thirds of the increments in mortality 
can be explained by natural causes . The use of certain atypical antipsychotics has lead to 
the rise of metabolic syndromes resulting in increased incidence of type 2 diabetes and 
ending in cardiovascular events that takes lives (Auquier, Lancon et al. 2007). However, the 
increased prevalence of medical conditions can also be due to other factors such as 
sedentary lifestyle, smoking, hereditary and unhealthy diets. Under recognition and 
inadequate treatment of co morbid medical conditions and an increased likelihood of 
adverse outcomes of some treatments for co morbid medical conditions also contribute to 
the rise of mortality in schizophrenia (Tandon, Nasrallah et al. 2009). Suicide remains one 
of the major cause of death in schizophrenia and claims 9-13% life of schizophrenic 
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patients (Meltzer 1999). Suicide can be prevented with early detection and commencement 
of treatment in schizophrenia patients.  
1.4.2 NEUROBIOLOGY OF SCHIZOPHRENIA  
1.4.3. NEUROPATHOLOGICAL AND NEURANATOMICAL  
In contrast to Alzheimer‘s disease, that has diagnostic neuropathology, which is 
quantifiable and correlates with the clinical severity of the disorder, the same cannot be said 
for schizophrenia (PJ Harrison 2005). Based on the success of understanding the 
neuropathological and neurodegenerative basis for Alzheimer disease, Parkinson disease 
Huntington‘s disease and related polyglutamine diseases suggests some potential lessons 
for schizophrenia (Ross, Margolis et al. 2006) .  
There is no ―pathognomonic‖ neuropathological changes identified in schizophrenia, the 
changes are more subtle. Despite this there are several important observations are made 
over time, using neuroimaging studies , advance histochemicals study , receptor 
autoradiography, in situ hybridization and gene array techniques (Keshavan, Tandon et al. 
2008). There is evidence of structural brain abnormalities in schizophrenia which is , 
reduced brain weight , enlarged third and lateral ventricle and reduced cortical gray matter 
weight and related structures (Lewis and Lieberman 2000).Studies have consistently shown 
absence of glial proliferation (Arnold, Trojanowski et al. 1998) and Golgi studies showed 
reduction in the synapse rich neuropil (Selemon and Goldman-Rakic 1999). Synaptic 
connectivity in schizophrenia may be impaired ranging from the dendritic tree to cell body, 
axon terminal, synaptic terminal and associated glial elements (PJ Harrison 2005). 
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The neurochemical phenotypes involved in schizophrenia are unclear; as such several are 
implicated including glutamate deficits in the hippocampus and cerebellum. There are 
alterations of GABAergic as well as glumatergic synaptic populations in dorsolateral 
prefrontal cortex (DFPC), changes in cortical dopaminergic innervations and signaling 
(Lewis 2000). Many of these structural abnormalities are present in first episode psychosis, 
treatment naïve individuals with schizophrenia. They may be present prior to onset of 
illness which suggests they are primary disease process and not secondary to illness or 
consequence of treatment(Lewis and Lieberman 2000).  
Neuroanatomical findings have evolved with advanced neuroimaging techniques, MRI 
findings confirms structural brain abnormalities in schizophrenia. Among the changes seen 
using MRI is ventricular enlargement, medial temporal lobe involvement (includes 
hippocampus and parahippocampal gyrus, amygdala , superior temporal gyrus , parietal 
lobe involvement as well as subcortical brain region involvement. The subcortical region 
includes cerebellum, basal ganglia, corpus callosum , thalamus and Cavum septi pellucidim 
(CSP) (Shenton, Dickey et al. 2001) . Meta analysis of first episode schizophrenia have 
shown whole brain and hippocampal volume reductions (Steen, Mull et al. 2006). It has 
been suggested that development of cerebral asymmetry and anomalies in cerebral 
dominance is critical in the pathogenesis of schizophrenia and  could be related to 
susceptibility genes (Crow, Ball et al. 1989). 
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1.4.4. NEUROENDOCRINE IN SCHZOPHRENIA  
The stress diathesis model has long been discussed for Schizophrenia, Rosenthal, 1970 
postulated that the behavioral expression of the biological vulnerability for schizophrenia is 
influenced by exposure to stress. Stress is commonly associated with the index psychotic 
episode and the subsequent relapses (Norman and Malla 1993). As we know when an 
individual is in ‗stress‘ they will go into the flight or fight mode that activates the 
Autonomic Nervous System (ANS) and Hypothalamic Pituitary Adrenal (HPA) system. 
These reactions constitute the biological stress response that is typically associated with 
behavioral change (Elaine F. Walker 1997) . 
There are 3 chemical substances released by the HPA axis which are corticotropin releasing 
hormone, adrenocorticotropic hormone and glucocorticoid. During a stressful period, there 
is increased release of these chemical substances and most studies looks at cortisol levels 
and post dexamethasone levels. Cortisol is the major glucocorticoid hormone in humans. 
Glucocorticoids have effects throughout the body and they are critical to the physiological 
changes glucocorticoid receptors (GRs) located in various regions throughout the brain 
serve to regulate the activity of the HPA axis. The hippocampus contains a particularly high 
density of GRs, and it is believed to play an important role in the feedback system that 
serves to modulate the activation of the HPA axis (Keshavan, Tandon et al. 2008). If an 
individual is continuously in a stressful state it will cause permanent changes to the HPA 
axis and subsequent damage to the hippocampus. Hippocampus damage has been linked to 
the neurotoxic effects of excessive glutamate release, which is potentiated by  
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glucocorticoids (Elaine F. Walker 1997). Animal studies showed that chronic stress and/or 
high glucocorticoid levels induces deleterious effects on neuroplasticity (McEwen 2008).  
A large number of studies reported that baseline cortisol levels are higher in schizophrenic 
individuals than controls, the cortisol levels are higher in prefrontal cortex and 
Cerebrospinal fluids of schizophrenics (Issa, Zhan et al. 2010) . The dexamethasone 
suppression test (DST) is typically used with psychiatric patients as a challenge to the HPA 
axis, with the goal of assessing the integrity of HPA regulation by means of feedback 
mechanisms (Elaine F. Walker 1997).A systematic review revealed that incidence of 
dexamethasone non suppression, a measure of HPA axis overactivation is significantly 
higher in schizophrenia than controls (Yergani 1990) .The post dexamethasone cortisol 
levels were dependent on phase of illness and medication status. Elevated cortisol post DST 
levels is seen preceding a psychotic episode compared to during recovery period (Sachar 
1970) and in individual with severe negative symptoms ( Walker et al,1997). Furthermore, 
elevated cortisol secretion in psychotic individuals has been linked with greater symptoms 
severity, impaired cognition and ventricular enlargement (Tandon, Mazzara et al. 1991) .  
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1.4.5. NEUROTRANSMITTER IN SCHIZOPHRENIA 
There are few neurotransmitters implicated in schizophrenia and the oldest and widely held 
for schizophrenia is dopamine. In 1950s, the accidental finding of phenothiazine ability to 
treat the positive symptom of schizophrenia put more emphasis on the dopamine hypothesis 
of schizophrenia. This theory postulates that dopamine dysfunction leads to manifestation 
of schizophrenia symptoms (Arvid Carlsson 1999) .In the early years there was no direct 
evidence to support this theory and with evolution and progression of research there is some 
evidence to lend support to this theory . As classically described by Von Rossum, 1967, the 
over activity of dopeminergic pathways causes the elevation of dopamine and symptoms of 
schizophrenia. Furthermore elevation of dopamine release in basal ganglia is seen after 
amphetamine challenge and this correlates to the induction of psychotic symptoms 
(Laruelle, D'Souza et al. 1997). Baseline elevation of dopamine in schizophrenic patients 
who are treatment naïve very tightly correlates with amphetamine induced dopamine 
release. In contrast to the original theory of dopamine hyperactivity, there is a new theory 
of dopamine hyper function. The theory suggested that unknown development or for 
biochemical reasons, causing a primary defect and disrupts the efficient, tight dopaminergic 
transmission, triggering feedback activation and receptor upregulation resulting in increase 
dopaminergic tone (Arvid Carlsson 2006). 
In recent years, other aberrations of neurotransmitters are looked into and whether their 
dysfunction would lead to schizophrenia. Lately, there is more interest in the role of 
Glutamate in schizophrenia. Glutamate is an excitatory neurotransmitter and widely found 
in the Central Nervous System (CNS). It is not only involved in fast synaptic transmission 
but also plays a role in neuroplasticity and cognitive function (Tsapakis and Travis 2002). 
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The reduced glutamate level in the cerebrospinal fluid of patients with schizophrenia was 
reported in 1980 by Kim et al, that initially lead to glutamate hypothesis of schizophrenia 
(Kim, Kornhuber et al. 1980). The deficiency of glutamate function at N-methyl-D-
aspartate (NMDA) receptors can produce psychotic symptoms. Findings that provide 
supports this hypothesis came from studies using neuroimaging such as positron emission 
tomography (PET) scan. It was shown that glutamate receptor function seem to be 
abnormal or function abnormally in patients with positive symptoms of schizophrenia 
(Tamminga 1998) . Other evidence is the clinical observations of psychotic symptoms 
induced by Phencyclidine (PCP) a NMDA-receptor antagonist and ketamine (Javitt 1991). 
Post mortem studies also detected a large number of abnormalities in the expression of 
GLU-related proteins especially NMDA receptor subunits most significantly the 
hippocampus and prefrontal cortex (Harrison, Law et al. 2003) , but few of these 
observations have been independently replicated .  
GABA dysfunction has long been postulated as a theory for schizophrenia .Postmortem 
brain studies of schizophrenic patients have shown that glutamic acid decarboxylase 
(GAD), the enzyme responsible for the synthesis of GABA as well as the uptake and 
release of GABA is reduced. GABA play an important role in the circuitry of the PFC 
which we know is also affected in schizophrenia patients. A postmortem study has found 
that the density of GABA membrane transporter 1 (GAT-1) immunoreactive chandelier 
neuron axon cartridges was decreased by 40% in schizophrenic subjects compared to both 
normal control and those with other mental illness (Woo, Whitehead et al. 1998). GAT-1 is 
the principal neuronal transporter for GABA.  
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Thus if any alteration in GAT-1 protein would also affect GABA concentrations, decreased 
GAT-1 levels is associated with elevated GABA concentrations which causes increased 
inhibitory effects and a reciprocal decrease in the excitatory output of chandelier neuron 
axon (David A 2000). Other studies have identified that treatment with NMDA antagonist 
for a period of days can cause reduction of cortical glutamate decarboxylase67 (GAD67) 
and parvalbumin mRNA which would lead to expected reduction in GABA levels and 
therefore decrease inhibition. How can this occur? Pyramidal cells activity is monitored by 
NMDA channel which acts as a sensor. If the channel malfunction suggesting low 
pyramidal cell activity, interneuron may synthesize less GABA and parvalbumin, in order 
to restore pyramidal cell activity to the normal level. However if the homeostatic loop 
malfunctions too , it could lead to produce over activity of pyramidal cell activity and 
eventually the symptoms of schizophrenia will occur (Lisman, Coyle et al. 2008). The 
importance of malfunction of the PFC circuitry is that it alters GABA level causing 
GABAergic hypofunction. This leads to clinical manifestation of Schizophrenia such as 
poor memory, poor affect regulation and altered working memory (Shulman 2005). It is 
hypothesized that there is a feedback loop that helps regulates dopamine, GABA and 
glutamate neurotransmitters. For example hypofunction of NMDA receptor removes the 
excitatory drive to inhibitory GABAergic neurons. The GABAergic neurons in return 
regulates non –NMDA excitatory neurons. These neurons acts on the frontal cortex and the 
limbic regions, leading to reduced inhibitory control, increasing firing resulting in psychotic 
symptoms  being produced (Farber 1998). This suggests that interactions between GABA 
and glutamate can influence their function and subsequently lead to manifestation of 
schizophrenia symptoms. 
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1.4.6. GENETICS OF SCHIZOPHRENIA  
It was suggested by Kallman, 1946 that there is a genetic basis for schizophrenia however 
due to lack of research tools in the early years this illness was mainly thought due to 
dysfunctional family dynamics as described by Bateson , 1965 and Lidz , 1965 
(Benjamin.J.Sadock 2007). However as time progresses it has become more evident there is 
a genetic basis to this illness as schizophrenia seems to aggregates in families (Tandon R 
2008) . If a family member is affected the risk of developing schizophrenia increases. The 
higher the genetic affinity of the affected family member the likelihood of having 
schizophrenia increases. Data from family, twin and adoption further substantiates this 
genetic basis. Twin studies have shown incidence of schizophrenia in dizygotic twins is 
about 17% of affected individuals and in monozygotic twins incidence up to 50% 
(Gottesman 1991). Furthermore, adoption studies demonstrated that the risk of 
schizophrenia is related to the presence of the disorder in biological parents and not in the 
adoptive parents (Gottesman 1982).  
Finally, family studies have reported the incidence of schizophrenia is 2% in third degree 
relatives (e.g., first cousins) of an individual with schizophrenia, 2%–6% for second degree 
relatives (e.g., nieces/nephews), and 6%–17% in first degree relatives (e.g., parents, siblings 
or children) (Gottesman 1991).These family studies have shown that simple major genes 
affected is unlikely instead polygenic models more plausible that is multiple genes are 
affected leading to this illness. Hence like diabetes, cancer and heart disease schizophrenia 
is a complex genetic disorder, it is not caused by defect of a single gene and neither does it 
have simple patterns of inheritance. In fact there is multiple interacting risk alleles, each 
accounting for only a small increment in risk (PJ Harrison 2005). What we know is 
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heritability is high in families with affected family members and genetic factors contribute 
80% liability for schizophrenia. At the moment there is no diagnostic biomarker for 
schizophrenia and further studies need to be carried out. Biomarkers‘ in schizophrenia can 
be a tremendous help to chart the phenotypic variation in the course, outcome and response 
to treatment (Keshavan, Tandon et al. 2008). 
 
1.4.7. NEUREGULIN 1 (NRG 1) AND SCHIZOPHRENIA 
The neuregulins consists of 4 genes and neuregulin 1(NRG1) is the most well characterized 
member of the family, it is important in many organs including heart, breast and nervous 
system (Harrison and Law 2006). The human NRG1 gene is located on chromosome 8p13, 
past few years new discoveries has been made , until recently there were only 3 types of 
NRG 1 that is known (types I-III) however recent transcripts containing additional 5‘ exons 
were found in the human brain , the novel types of NRG 1 proteins are called types IV–
VI(Steinthorsdottir, Stefansson et al. 2004). NRG 1 is a pleiotropic growth factor that is 
important in CNS development and function (Li, Collier et al. 2006). NRG 1 has a 
multitude of function , it is involved in the modulation of neuronal migration, 
synaptogenesis, gliogenesis, neuron –glia communication, myelination and 
neurotransmission in the brain and other tissues(Stefansson, Steinthorsdottir et al. 2004).  
How is it involved in schizophrenia? Based on the glutamate hypothesis of schizophrenia 
whereby psychotic symptoms can be produced by decreased glutamatergic function at 
NMDA receptors or increased glutamatergic function at AMPA and kainate receptors 
(Tsapakis and Travis 2002). NRG 1 is reported to play a role in regulation of NMDA 
receptors expression and glutamate signaling pathways (Ozaki, Sasner et al. 1997) and it 
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also modulates neurotransmitter release from GABAergic interneurons. Dysfunction of 
NRG1 in schizophrenia, could explain in part, the apparent deficiency in glutamate-receptor 
expression and binding described within in some parts of brains of schizophrenia 
patients(Huang, Won et al. 2000). In a landmark study in 2002 , Stefansson et al reported an 
association between NRG 1 and schizophrenia following extensive fine-mapping of the 8p 
locus and haplotype-association analysis, supplemented by a transmission/disequilibrium 
test, identifies neuregulin 1 (NRG1) as a candidate gene for schizophrenia. Researchers also 
found 16% fewer functional NMDA receptors in the NRG 1 mutant mice which is in 
keeping with reports suggesting a role for NRG1 in regulation of NMDA subunit 
expression(Ozaki, Sasner et al. 1997). 
 
The chromosome 8p has been highlighted as a susceptibility locus for schizophrenia based 
from genome wide association studies and meta analysis linkage scans (Stefansson, 
Sigurdsson et al. 2002). Studies have been conducted in both Caucasian and Asian 
population to see the association between NRG 1 and schizophrenia. It is found that these 
studies support NRG 1 as a schizophrenia susceptibility gene despite having differing 
results. The Icelandic study identified a ‗‗core at-risk haplotype‘‘ consisting of five SNPs 
(SNP8NRG221132, SNP8NRG221533, SNP8NRG241930, SNP8NRG243177, and 
SNP8NRG433E1006) and two microsatellites D8S181029 and H12-121L21(deCODE 
haplotype). Whereas family studies done in Han Chinese population, identified different 
SNP‘s at risk SNP8NRG221533, SNP8NRG221132 and D8S1770. In a later study in 2006, 
it found up-regulation of type I expression in the hippocampus in schizophrenia, (ii) 
association of type I expression with a single SNP residing in the original deCODE risk 
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haplotype, and (iii) association of type IV expression with a single SNP and a four-marker 
haplotype representing the 5_upstream region of the original at-risk haplotype associated 
with schizophrenia. The evidence of altered NRG 1 isoform expression in the brain and 
disease linked variation in NRG 1 , suggest that alteration of transcript regulation is a 
potential molecular mechanism behind the genetic association of NRG1 with schizophrenia 
(Amanda J. Law and Ryota Hashimoto 2006). 
 
1.4.8. NEUREGULIN 1 (NRG 1) POLYMORPHISM AND ASSOCIATION WITH 
ANTIPSYCHOTICS 
Genome wide scans supported the association between schizophrenia and NRG 1, 
significant evidence for linkage has been reported in three chromosomal regions. These 
three regions are located on chromosome 6p24-22, chromosome 13q32 and of course 
chromosome 8p21-22. It is chromosome (8p21-p12; Neuregulin 1) that presents evidence 
for NRG1 as a Schizophrenia candidate gene (Lewis, Levinson et al. 2003). The increased 
risk for schizophrenia has been postulated due to abnormal signaling of glutamatergic and 
dopaminergic pathways in the brain. One of the identified functions of NRG 1 is to help 
upregulate N-methyl-D-aspartate glutamate (NMDA) receptors. It is also likely responsible 
for regulating synaptic connectivity and plasticity (Ozaki M and . 2000). Even though there 
are discrepancies or inconsistencies, bulk of data have shown that either an increase of 
NRG 1 isoform (protein or mRNA) expression or increased ErbB4 receptors (protein or 
mRNA) expression. This may highly indicate that, NRG1–ErbB4 signaling and expression 
to be increased in schizophrenic subjects, although some studies have shown decreased 
expression of NRG1/ErbB4. Thus, the enhanced NRG1 signaling may contribute to N-
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methyl-D-aspartate (NMDA) receptor hypofunction in schizophrenia (Hahn, Wang et al. 
2006). Finnish study use one SNP (SNP8NRG221533) as a genetic marker to compare the 
allele frequencies of Neuregulin 1 in patients with schizophrenia and control subjects. The 
schizophrenic group was divided into responders and non responders, the responders were 
treated with conventional antipsychotics whereas those non responders were given 
clozapine. The study found NRG1 genotype or allele frequencies showed similar 
distributions between patient and control groups. However, TT genotype was 
overrepresented in the non-responders group compared with the responders. (Olli 
Kampman and Esa Leinonen 2004). In another study conducted in Han Chinese, NRG 1 
mRNA was compared between two groups. One group was treated with risperidone and the 
other with quetiapine, the NRG 1 expression after 4 weeks on treatment showed no 
significant difference between the two. Interestingly, the antipsychotics did have an effect 
on NRG 1 mRNA expression. After 4 weeks on treatment , the NRG 1 mRNA increased 
which suggest antipsychotics regulates positively the expression of NRG 1 (Hong-Xing 
Zhang  and Xuan Ouyanga 2008). 
 
Further studies lend support to this theory , haloperidol, clozapine and risperidone have all 
been found to increase NRG1 and ErbB4 expressions but not in the prefrontal cortex of 
animal tissue after 4 weeks on treatment (Wang X-D 2008). In a cross sectional study using 
peripheral blood, the NRG 1 expression was evaluated using immortalized lymphocytes. 
Twelve schizophrenic and twelve controls lymphocytes were grown individually with or 
without the presence of the antipsychotic olanzapine. Findings showed that before and after 
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olanzepine stimulation there were no alteration of NRG 1 RNA expressions in immortalized 
lymphocytes and in either of the isofroms studied (Chagnon, Roy et al. 2008). 
There are still inconsistencies among studies in regards to antipsychotic effect on NRG1 
expression, in general short term treatment with antipsychotics (up to 4 weeks) increases or 
upregulates the expression (mRNA or protein) of NRG1 isoforms and ErbB4 receptors. 
Whereas, long term treatment or continuous treatment with antipsychotics (at least 12 
weeks) decreases or downregulate their expression (at least at protein level). These effects 
may be due to multiple binding profiles with various G-coupled protein receptors (e.g. 
dopamine, and serotonin receptors) of antipsychotics. Unfortunately, why does this 
phenomenon occur is still unclear.  
 
There are several reasons why this may occur; NRG1 and ErbB4 expression and signaling 
are affected differently by the multiple and varied antipsychotics and is also dependent on 
treatment duration. Apart from that, the studies conducted used different various types of 
tissue such human tissue (for example postmortem studies using brain tissue from different 
regions (such as Prefrontal Cortex) or human blood (PBL‘s), some studies used animal 
tissue ( for example rats PFC) . As such this can affect the outcome of the studies due to the 
differing mediums used. Studies are needed to investigate the interactions between NRG1–
ErbB4 and the other signaling pathways (such as glutamatergic, GABAergic and 
dopaminergic). Furthermore, the interactions between NRG1/ErbB4 and other 
schizophrenia susceptibility genes under antipsychotic treatment also require 
investigation(Bo Pan 2011). 
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1.5. ANTIPSYCHOTIC PHARMACOLOGY  
The treatment of schizophrenia has come a long way  starting with the incidental discovery 
of chlorpromazine (CPZ) by Laborit which open up the field of psychopharmacology (Tost, 
Alam et al. 2010).The accidental discovery of antipsychotic spurred interest in the 
neurobiological basis of psychosis , among which give rise to the dopamine hypothesis . 
This discovery leads to further development of antipsychotics, from conventional 
antipsychotics to atypical group of antipsychotics. Atypical antipsychotics are considered to 
be standard treatment of care and this is evident in most countries guidelines. This group of 
antipsychotics have demonstrated efficacy for a broader spectrum of symptoms than 
conventional antipsychotics, and have a lower propensity to cause side effects such as 
movement disorders (Jones 2010). 
1.5.1.PALIPERIDONE 
Description  
Paliperidone is an orally administered antipsychotic and the principal active metabolite of 
risperidone (9-hyroxyrisperidone). In Malaysia it has been approved for the acute treatment 
of Schizophrenia as well as for recurrence prevention. In UMMC the available form is 
paliperidone ER or also known as Invega and it is this form used for this study. It is 
available as prolonged-release capsules (orange-brown: 1.5 mg; white: 3 mg; beige: 6 mg; 
pink: 9 mg; yellow: 12 mg), prolong release means that drug release gradually occurs. 
paliperidone ER is formulated using OROS®(osmotic controlled-release system, ALZA 
corporation,CA, USA) technology, which reduces peak to-trough variations in plasma 
concentrations and eliminates the need for initial dose titration (Eerdekens M 2006). 
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Paliperidone resembles a capsule shaped tablet in appearance, comprises of an osmotically 
active trilayer core surrounded by a subcoat and semipermeable membrane. The trilayer 
core is composed of two drug layers containing the drug and excipients and a push layer 
containing osmotically active component. Each strength is identified by a unique colour 
overcoat and print markings. Paliperidone also contain the following inactive ingredients 
carnauba wax, cellulose acetate, hydroxyethyl cellulose, propylene glycol , povidone, 
sodium chloride, stearic acid , butylated hydroxytoluene, hypromellose, titanium dioxide 
and iron oxides. The 3mg tablets also contain lactose monohydrate and glycerol triacetate.  
Clinical pharmacology  
Pharmacodynamics  
Paliperidone is a centrally active dopamine D2 antagonist with predominant serotonergic 5-
HT2A antagonistic activity paliperidone also blocks alpha1-adrenergic receptors and 
blocks, to a lesser extent, H1-histaminergic and alfa2-adrenergic receptors. Paliperidone is 
not bound to cholinergic receptors beta 1 and beta 2 adrenergic receptors. Even though 
paliperidone is a strong D2-antagonist, which is believed to relieve the positive symptoms 
of schizophrenia, it causes less catalepsy and decreases motor functions to a lesser extent 
than traditional neuroleptics. Dominating central serotonin antagonism may reduce the 
tendency of paliperidone to cause extrapyramidal side effects. Positron emission 
tomography (PET) studies, suggest that paliperidone ER dosages between 6 and 9 mg/day 
result in a D2 receptor occupancy of 70–80% (a range which is associated with optimal 
efficacy. Paliperidone ER dosages above 19.6 ng/mL were associated with >80% D2 
receptor occupancy and are therefore more likely to be associated with extrapyramidal 
adverse events (Keating 2010). 
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Pharmacokinetics  
Absorption  
Following a single dose paliperidone exhibits a gradual ascending release rate, allowing the 
plasma concentrations of paliperidone to steadily rise to reach peak plasma concentration 
(Cmax) approximately 24 hours after dosing. With once-daily dosing of INVEGA, steady-
state concentrations of paliperidone are attained within 4-5 days of dosing in most subjects. 
The absolute oral bioavailability of paliperidone following INVEGA administration is 28% 
(90% CI of 23%-33%). Administration of paliperidone prolonged-release tablets with a 
standard high-fat/high-caloric meal increases Cmax and AUC of paliperidone by up to 50-
60% compared with administration in the fasting state. 
Distribution  
Paliperidone is rapidly distributed the apparent volume of distribution is 487 L. the plasma 
binding of Paliperidone is 74%.It binds primarily to alpha 1 acid glycoprotein and albumin. 
Metabolism & Elimination  
Paliperidone ER is only minimally metabolized in the liver and is primarily eliminated via 
renal clearance. Thus it has a lower potential for clinically significant pharmacokinetic drug 
interactions with drugs that are metabolized by the cytochrome P450 (CYP450) enzyme 
system. One week following administration of a single oral dose of 1 mg immediate-release 
14
C-paliperidone, 59% of the dose was excreted unchanged into urine, indicating that 
paliperidone is not extensively metabolised by the liver. Approximately 80% of the 
administered radioactivity was recovered in urine and 11% in the feaces. Although in vitro 
studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, there 
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is no evidence in vivo that these isozymes play a significant role in the metabolism of 
paliperidone. Population pharmacokinetics analyses indicated no discernable difference on 
the apparent clearance of paliperidone after administration of paliperidone between 
extensive metabolisers and poor metabolisers of CYP2D6 substrates. In vitro studies in 
human liver microsomes showed that paliperidone does not substantially inhibit the 
metabolism of medicines metabolised by cytochrome P450 isozymes, including CYP1A2, 
CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5. Four metabolic 
pathways were identiﬁed as being involved in the elimination of 9-OHR, each of which 
accounted for up to a maximum of 6.5% of the biotransformation of the total dose. 
Biotransformation of the drug occurred through oxidative N-dealkylation, 
monohydroxylation of the alicyclic ring, probably by CYP2D6, alcohol dehydrogenation, 
and benzisoxazole scission, the latter incombination with glucuronidation or alicyclic 
hydroxylation. Once ingested, paliperidone undergoes directly phase 2 metabolism 
(conjugation reactions) or is excreted unchanged in the urine, which makes it the 
antipsychotic with the lowest potential of inducing pharmacokinetic drug-drug interactions 
(Meyer 2007).Paliperidone had a terminal elimination half life (t½b) of approximately 23 
hours in patients with normal renal function (http://www.ema.europa.eu). 
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1.5.2 Drug-drug interaction  
Limited data are available regarding drug interactions with paliperidone ER. However, 
paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9 and CYP2C19; thus, 
clinically important interactions between paliperidone and other drugs metabolized by CYP 
isoenzymes are not expected. Interaction between paliperidone and organic transport 
inhibitors is not expected.(Agency.). There is data that shows co administration of 
paliperidone with carbamazepine will lower the plasma concentration of 9-
hydroxyrisperidone probably by inducing CYP3A4 mediate metabolism. In contrast co 
administration with sodium valproate does not cause any change(Spina E 2000). 
 
1.5.3 Clinical Efficacy Trials in Schizophrenia  
The efficacy of antipsychotics has long been debated whether it the typical or atypical 
antipsychotics works better. Pragmatic trials such as Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) (Lieberman JA and Keefe RSE 2005) and Cost Utility 
of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) (Jones PB and 
Markwick A 2006) demonstrated high discontinuation rates across all antipsychotics . In 
CATIE the lowest discontinuation rate was for olanzepine phase 1 and clozapine in phase 2. 
The outcome in CUtLASS whereby in phase 1 patients on FGA and SGA showed no 
significant differences in life measures or schizophrenia symptoms and in phase 2 , 
clozapine was found to be more effective than any SGA in reducing symptoms but not 
quality of life (Constantine 2007). The reason for discontinuation cited is lack of efficacy , 
switching, side effects or patients choice (Lewis 2008). This reflects the need for an 
antipsychotic that is not only tolerable but also efficacious. The efficacy of paliperidone in 
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the treatment of Schizophrenia was evaluated in 1,690 adult subjects with schizophrenia 
who participated in 3 double blind 6-week, multicenter, randomized, placebo controlled 
study of whom 1,394 received paliperidone ER at fixed doses, the outcome was consistent 
in each trial. In a clinical trial whereby 444 adult subjects with schizophrenia who 
participated in a placebo controlled 6 week trials , of which 432 subjects received 
paliperidone ER at fixed doses ranging from 6mg to 12mg once daily. Those on 
paliperidone ER showed significant improvement in mean total PANSS score compared to 
placebo. The 3mg paliperidone ER group showed improvement in mean PANSS total score 
from day 4 and day 15 from 12mg group respectively (Marder, Kramer et al. 2007). 
Long term efficacy studies has been conducted for paliperidone ER , in a analysis of pooled 
data from three separate 52-week, international, multicenter, open-label studies with 
flexible dosing of paliperidone ranging from 3mg to1 5mg showed improvement in PANSS 
total, PANSS Marder factor, and CGI-S scores were observed for those patients completing 
52 weeks of paliperidone ER therapy. Long term treatment with paliperidone ER was 
generally safe and well tolerated, with no unexpected AEs emerging over the study period, 
and was associated with a favorable metabolic profile (Emsley, Berwaerts et al. 2008). In 
another long term study which assessed the efficacy of paliperidone ER in delaying 
symptom recurrence in adults with Schizophrenia data demonstrated significant efficacy in 
delaying recurrence of symptoms in stabilized patients. (Kramer, Simpson et al. 2007). 
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1.5.4. Side effects 
Adverse events are defined as untoward occurrence including undesirable sign & 
symptoms, disease or accidents or abnormal findings (leading to dose reduction / 
discontinuation / intervention). Treatment emergent adverse events is defined as any event 
not present prior to treatment or worsened in either intensity or frequency while undergoing 
therapy after baseline evaluation. Adverse events that occur during clinical trials are 
obtained by investigators and recorded using tools and terminology of their own choosing. 
Meta analysis by Jones et al, whereby 31 studies evaluated with total of 5313 subjects of 
which 851 received paliperidone ER. For atypical antipsychotics as a group, the odds of 
withdrawal due to AEs were similar to placebo (OR 1.02; 95% CI 0.83, 1.25). The OR for 
withdrawal due to AEs was lower with paliperidone ER (OR 0.88; 95% CI 0.67, 1.15) than 
risperidone (OR 2.09; 95% CI 0.8, 5.41). In 3 acute efficacy trials with paliperidone ER 
treatment emergent adverse events was reported in 66-77% of patients in the paliperidone 
group compared with 66% in the placebo group (Meltzer H 2006).  
1.5.5 Incidence of adverse events in placebo controlled clinical trials for schizophrenia  
In 3 acute efficacy trials with Paliperidone ER, among the commonly reported adverse 
events are headache, agitation, anxiety and insomnia at 12%, 8% and 4% respectively. 
serious adverse events in paliperidone ER group (5-6%) is comparable to placebo group 
(6%).Incidence of extrapyramidal symptoms (EPS) was EPS was comparable between the 
paliperidone ER 3mg and 6mg groups (13% and 10% respectively) and placebo 11% 
(Meltzer H 2006). Dose relatedness for EPS was seen with the 2 higher doses of 
paliperidone ER 9mg (25%) and 12mg (26%) respectively. Pooled data from 3 placebo 
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controlled, 6 week fixed dose studies showed comparable weight gain between paliperidone 
group on 3mg and 6mg ( 7% and 6% ) compared with placebo (5%). For the 2 higher doses 
9mg and 12 mg weight incidence is 9% for both dose. In both genders that received 
paliperidone e ER serum prolactin levels noted to increase after commencing treatment 
from 3 6 week double blind placebo controlled, fixed dose studies. paliperidone ER causes 
modest increase in the corrected QT interval (QTc), the incidence of QTc prolongation on 
paliperidone ER ranged from 3% to 5% compared with 3% on placebo. paliperidone ER 
should also be avoided in patients with congenital long QT syndrome or a history of cardiac 
arrhythmias and avoided in combination with drugs that are known to prolong QTc interval 
(http://www.ema.europa.eu).  
 
 
1.6 RATIONALE OF STUDY  
Studies conducted previously on NRG 1 as a susceptibility gene for Schizophrenia  were 
done in the Western population (Stefansson, Sigurdsson et al. 2002) which mainly consists 
of Caucasians and studies done in Asian population was carried out in China and the 
subjects were Chinese of Han descent only (Li, Collier et al. 2006). Hence it will be 
interesting to see what result will come out of a multiracial population such as ours. 
Pharmacogenomics is a relatively new area in Malaysia across all fields of medicine 
including Psychiatry; as such there is no published local data at the time study was 
conducted. Hence, this preliminary study was designed to determine whether there is 
alteration of NRG 1 gene expression in schizophrenic patients in our local population.  
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1.6.1 GENERAL OBJECTIVE  
To investigate gene expression of Neuregulin 1(NRG 1) in Schizophrenia patients on 
paliperidone in a Malaysian population.  
1.6.2 SPECIFIC OBJECTIVES  
1. To investigate the expression of Neuregulin 1 (NRG 1) in Schizophrenic patients on 
paliperidone in a Malaysian population from peripheral blood. 
2. To determine the association between NRG 1 level and symptomatology of 
schizophrenia. 
3. To assess motor related adverse events in study subjects  
 
1.7 RESEARCH HYPOTHESIS  
There is altered gene expression of NRG 1 in Malaysian population with Schizophrenia 
patients which would be influenced by paliperidone treatment. 
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CHAPTER 2: METHODOLOGY 
2.1 STUDY SETTING  
The study was conducted at the University Malaya Medical Centre (UMMC). UMMC is 
located on the border of Kuala Lumpur and Petaling Jaya (PJ) cities. Its catchment area is 
the population of PJ. The majority of residents are of Chinese descent, middle income 
group, educated and urbanized. Chinese form 40 percent of PJ residents 37 percent are 
Malays, 16 percent are Indians and 7 percent are other races. UMMC is the oldest teaching 
hospital in the country. It was established in 1965 and continues to provide services to 
Klang Valley residents. The faculty of Medicine helps to provide the manpower needed to 
run this great establishment. The faculty prides itself for its outstanding undergraduate and 
postgraduate course that places great emphasis on research. Hopefully the research carried 
out will benefit the nation.  
In UMMC there are several services available to the community and one of those is 
psychiatry services which includes clinics. The psychiatry clinic is open daily, includes 
walk in new case clinic, walk in old case clinic and clinic for scheduled appointments. 
There are also various sub specialty clinics available on allocated days such as adult liaison, 
psycho-oncology, psychogeriatric, memory, addiction, compliance and child clinic. 
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2.2. STUDY DESIGN 
This is a cross sectional study looking at the NRG 1 gene expression level in schizophrenic 
patients on paliperidone and comparing it with a control group. The control group NRG 1 
gene expression and socio-demographic data will also be assessed. 
2.3. SAMPLE SIZE 
In Malaysia there is no previous data in regards to data on gene polymorphism of NRG 1, in 
Asian population such studies has been carried out in Japan, China and Korea. Hence we 
determined our same size based on previous studies conducted in Asian population. We 
thought the gene expression findings of Asian population would be closer to our population 
than the Caucasian population. This study is largely based on a study conducted by group of 
researches (Hong-Xing Zhang  and Xuan Ouyanga 2008) that recruited 31 first onset 
schizophrenic patients (15 male and 16 female ) ,Chinese of Han descent. In this particular 
study they looked at the expression of neuregulin-1 gene in peripheral blood and results 
showed that NRG-1 mRNA expression in PBLs of schizophrenic were lower than the 
control group. However after treatment with antipsychotic the level of NRG-1 gradually 
increased. In a study done in a Caucasian population setting in Australia (Nikola A. 
Bowden  and Ulrich Schall 2006), the study of gene expression profiles in peripheral blood 
lymphocytes in schizophrenia only 14 schizophrenic patients were recruited and 14 non 
psychiatric control subjects . Hence, the decision was made to recruit at least 15 
schizophrenic subjects and 15 healthy controls. The subjects were recruited via the 
psychiatry services in UMMC based on convenience sampling. In the end a total of 20 
schizophrenic subjects were recruited for the study with 15 healthy controls. 
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2.3.1 INCLUSION CRITERIA  
1. Ages between 18 to 65 years old 
2. Able to give written informed consent  
3. Fulfils DSM-IV TR diagnosis of schizophrenia and confirmed by MINI 
4. Schizophrenic patients on paliperidone treatment for at least 4 weeks. 
2.3.2. EXCLUSION CRITERIA  
1. DSM-IV Axis I diagnosis other than schizophrenia 
2. DSM-IV diagnosis of substance dependence within 6 months prior to screening 
(nicotine and caffeine dependence are not exclusionary) 
3. significant risk of suicidal or violent behaviour  
2.3.3. Control sample 
Control group would be healthy volunteers with NO history of mental illness or family 
history of mental illness. The control group participants were attending UMMC. The 
control group is of multiracial origin who matched for age and gender for the schizophrenic 
patients as much as possible. The need for control without psychiatric illness is necessary to 
compare NRG 1 expression in this group to the schizophrenics. 
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2.4 DATA COLLECTION  
The study subjects were recruited from individuals who came into contact with psychiatric 
services at University Malaya Medical Center (UMMC) from February 2011 until 
November 2011. Those that fulfilled the inclusion and exclusion criteria were enrolled into 
the study .The diagnosis was confirmed using Mini International Neuropsychiatric 
Interview (M.I.N.I)., based on the diagnostic criteria for schizophrenia in Diagnostic and 
Statistical Manual of Mental Disorders ,Fourth Edition , Text Revision (DSM IV TR ). The 
patient as well as control was given a Patient Information Sheet and explained regarding the 
study. Once the person agreed to participate, he/she was asked to sign an Informed Consent 
Form. The demographic data will be collected by clinical interview and from the patient‘s 
medical records, following a pro-forma. 
The symptoms were assessed using Positive and Negative Syndrome Scale (PANSS) (Kay, 
Fiszbein et al. 1987). Adverse effects enquired from patients and reported by patients were 
documented. The compliance to treatment was determined by pill counting and verification 
from family. Venous blood was taken for each patient during their visits for gene analysis. 
Clinical side effects assessed using Barnes Akathisia Rating Scale (BARS) . 
2.5. STUDY MEASUREMENT  
2.5.1 IDENTIFICATION DATA  
Information collected includes socio-demographic data (age, gender, ethnicity, education 
level, marital status and employment status) and clinical characteristics. 
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2.5.2 CLINICAL DATA 
Among the clinical data collected were duration on treatment, the current dose of 
paliperidone and reported side effects by patients. 
2.5.3. MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I) 
The MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I) is a short 
and structured diagnostic interview, developed jointly by psychiatrists and clinicians in the 
United States and Europe , compatible with DSM-IV and ICD-10 psychiatric disorders. It 
inexpensive and easy to administer. Administering the MINI should not take more than 15 
minutes, as such it is designed to meet the need for short but accurate structured psychiatric 
interview that can be used internationally for clinical trials and epidemiology studies. The 
M.I.N.I has been compared to the Composite International Diagnostic Interview (CIDI) and 
the Structured Clinical Interview for DSM-IH-R patients (SCID). In respect to comparison 
with SCID – P were characterized by good or very good Kappa values (0.50-0.90), with 
only a single value for current drug dependence 0.43. In comparison to CIDI, Kappa values 
were also good or very good diagnoses with the exception of generalized anxiety disorder 
(GAD) (kappa = 0.36), agoraphobia (sensitivity = 0.59) and bulimia (kappa = 0.53). Inter-
rater and test-retest reliability were good, 0.79 to 1.00 as reported by the authors. 
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2.5.4. Positive and Negative Syndrome Scale (PANSS) 
The PANSS or the Positive and Negative Syndrome Scale is a medical scale developed in 
order to provide a well-defined instrument to specifically assess both positive and negative 
symptoms of schizophrenia as well as general psychopathology. It was developed in 1987 
by Stanley R. Kay, Abraham Fiszbein, and Lewis A Opler and widely used for research 
purposes. It combines 2 scales, 18 items of the Brief Psychiatric Rating Scale develop by 
Overall and Gorham, 1962) and 12 items of the Psychopathology Rating Schedule by Singh 
and Kay, 1975 and all items were given a complete definition as well as detailed anchoring 
criteria for all rating points. The scale consists of 30-item as an instrument for measuring 
the prevalence of positive and negative syndromes in schizophrenia. The patient is rated 
from 1-7 on 30 different symptoms based on interview with the patient as well as reports of 
family members or health workers. The scoring can be divided into 3 categories based on 
symptomatology : high if scores equal or more than > 95 , medium if in between > 75 and < 
95 , and low if score less than < 75 (Chris M Kozma 2010). 
 
2.5.5. Barnes Akathisia Rating scale (BARS)  
Akathisia is one of the side effects of antipsychotic that is relatively common and 
distressing to a patient. The Barnes Akathisia Scale (commonly known as BARS) is a rating 
scale that is administered by physicians to assess the severity of drug-induced akathisia and 
is derived to incorporate diagnostic criteria for pseudoakathisia. The severity of mild, 
moderate, and severe is based on objective and subjective assessment .It comprises items 
for rating the observable, restless movements which characterise the condition, the 
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subjective awareness of restlessness, and any distress associated with the akathisia. In 
addition, there is an item for rating global severity. The scoring for BARS as follows: 
Objective Akathisia, Subjective Awareness of Restlessness and Subjective Distress Related 
to Restlessness are rated on a 4-point scale from 0 – 3 and are summed yielding a total 
score ranging from 0 to 9. The Global Clinical Assessment of Akathisia uses a 5-point scale 
ranging from 0 – 4. The inter-rater reliability for the scale items (Cohen's x) ranged from 
0.738 to 0.955 (TR 1989). 
 
2.6. GENE EXPRESSION 
2.6.1. DNA extraction  
This was done using the Spin Protocol which is used to purify DNA from blood or body 
fluids. After recruiting a patient or control, blood was drawn and collected in 
ehtylenediamine tetraacetic acid (EDTA) tubes. After that EDTA blood tube was kept at a 
temperature of about – 800C . Next, 20 µl QIAGEN Protease (or proteinase K) was pipette 
into the bottom of a 1.5 ml microcentrifuge tube and 200 µl of the sample was added to the 
microcentrifuge tube. 20 µl Buffer AL was added to the sample which was mixed by pulse-
vortexing for 15 seconds. The sample then was incubated at 56
0
C for 10 minutes. The 1.5ml 
microcentrifuge tube was briefly centrifuged to remove drops from inside of the lid. 200 µl 
of ethanol (96-100%) was added to the sample and was mixed again by pulse-vortexing for 
15 seconds. After mixing, the 1.5ml microcentrifuge tube was briefly centrifuged again to 
remove drops from the inside of the lid. The above mixture was carefully applied to the 
QIAamp Mini spin column (in a 2 ml collection tube) without wetting the rim. The tap was 
closed and centrifuged at 8000 rpm for 1 minute. The QIAamp Mini spin column was 
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placed in a clean 2 ml collection tube and the tube containing the filtrate was discarded. The 
QIAamp Mini spin column was carefully opened and 500 µl Buffer AW1 was added 
without wetting the rim. The cap was closed and centrifuged at 8000 rpm for 1 minute. The 
QIAamp Mini spin column was placed in a clean 2 ml collection tube and the tube 
containing the filtrate was discarded. The QIAamp Mini spin column was carefully opened 
and 500 µl Buffer AW2 was added without wetting the rim. The cap was closed and 
centrifuged at 14000 rpm for 3 minutes. The QIAamp Mini spin column was placed in a 
clean 1.5 ml microcentrifuge tube and the tube containing the filtrate was discarded. The 
QIAamp Mini spin column was carefully opened and 200 µl Buffer AE or distilled water 
was added. This was incubated at room temperature for 1 minute and then was centrifuged 
at 8000 rpm for 1 minute 
2.6.2. RNA Extraction 
Manual Purification of Total RNA from human whole blood collected into PAXgene 
blood RNA tubes (BRT) 
The PAXgene Blood RNA Tube (BRT) was centrifuged for 10 minutes at 3000-5000 x g 
using a swing-out rotor. The supernatant is removed by decanting or pipetting. 4ml RNase 
free water (RNFW) was added to the pellet and the tube was closed using a fresh secondary 
BD Hemogard closure. The mixture was vortexed until the pellet was visibly dissolved and 
was centrifuged for 10 minutes at 3000-5000 x g using a swing-out rotor. The entire 
supernatant was removed and discarded. 350 µl resuspension buffer (BR1) was added and 
vortexed until the pellet was visibly dissolved. The sample was pipette into a 1.5ml 
miccrocentrifuge (MCT). 300 µl binding buffer (BR2) and 40 µl proteinase K (PK) were 
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added and mixed by vortexing for 5 seconds and incubated for 10 minutes at 55° using a 
shaker-incubator at 400-1400 rpm. After incubation, the temperature of the shaker- 
incubator was set to 65°. The lysate was pipette directly into a PAXgene Shredder spin 
column placed in a 2ml processing tube and centrifuged for 3 minutes at maximum speed 
(but not exceeding 20 000 x g). The entire supernatant of the flow- through fraction was 
carefully transferred to a fresh 1.5 ml microcentrifuge without disturbing the pellet in the 
processing tube. 350 µl ethanol was added and mixed by vortexing and centrifuged briefly 
to remove drops from the inside of the tube lid. 700 µl of sample was pipetted into the 
PAXgene RNA spin column placed in a 2ml processing tube and centrifuged for 1 minute 
at 8000-20000 x g. The spin column was placed in a new 2 ml processing tube and the old 
processing tube (PT) containing flow through was discarded. The remaining sample was 
pipette into the PAXgene RNA Spin column (PRC) and centrifuged for 1 minute at 8000-
20000 x g. The spin column was placed in a new 2 ml processing tube and the old PT 
containing flow-through was discarded. 350 µl wash buffer was pipetted into the PRC and 
it was centrifuged for 1 minute at 8000-20000 x g. The PRC was placed in a new 2 ml PT 
and the old PT containing flow-through was discarded. 10 µl DNase (RNFD) stock solution 
was added to 70 µl digestion buffer (RDD) in a 1.5ml microcentrifuge (MCT). It was mixed 
by gently flicking the tube and centrifuged briefly to collect residual liquid from the sides 
of the tube. The RNFD incubation mix was pipetted directly onto the PAXgene PRC 
membrane and placed on the bench top for 15 minutes. 350 µl wash buffer 1 was pipetted 
into the PAXgene PRC and centrifuged for 1 minute at 8000-20000 x g. The spin column 
was placed in a new 2 ml processing tube and the old PT containing flow-through was 
discarded. Another 500 µl wash buffer 2 was added to the PRC and centrifuged for 3 
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minutes at 8000-20000 x g. The PT containing flow-through was discarded and the 
PAXgene PRC was placed in a new 2 ml PT and centrifuged for 1 minute at 8000-20000 x 
g. The PT containing flow-through was discarded and the PAXgene PRC was placed in a 
1.5ml MCT and 40 µl elution buffer was pipette directly onto the PAXgene PRC membrane 
and was centrifuged for 1 minute at 8000-20000 x g to elute the RNA. The elution step 
above was repeated using 40 µl elution buffer and the same MCT. The elute was incubated 
for 5 minutes at 65° in the shaker incubator without shaking. After incubation, chill 
immediately on ice. If the RNA samples will not be used immediately, they should be 
stored at – 20° or -70° C. 
2.7. STATISTICAL ANALYSIS  
This data for this study was analyzed using Statistical Package for Social Sciences (SPSS) 
Version 17.0. Descriptive statistics were used to summarize the data.. To test for statistical 
significance, Mann Whitney U Test for categorical variable and spearman rho correlation. 
Exploratory data were carried out to check whether the data was normally distributed. Non-
parametric test were for non-normality distributed data. All test were two-tailed with results 
considered significant at p<0.05. 
2.8. ETHICAL CONSIDERATION  
Ethical approval was obtained from the Medical Ethics Committee, UMMC. The 
confidentiality of the participants was assured and the purpose of the study was explained to 
the participants. Written informed consent was obtained from all participants. 
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CHAPTER 3: RESULTS  
3.1 SAMPLE DESCRIPTION  
A total of 50 unrelated patients were approached but only 20 consented to join this study 
along with 15 healthy controls. 15 refused to participate, 10 were switched to other 
antipsychotic and 5 patients their diagnosis was changed to bipolar, schizoaffective 
disorder. 
3.2. SOCIO-DEMOGRAPHIC CHARACTERISTICS OF SCHIZOPHRENIA 
SUBJECTS 
3.2.1.AGE
                        Figure 1 Age Distribution of Schizophrenia Patients 
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Tests of Normality 
 Kolmogorov-Smirnova 
Statistic df Sig. 
Age  
.178 
 
20 
 
.098 
a. Lilliefors Significance Correction 
Table 1: Test of Normality for Age Distribution 
Figure 1 shows the distribution of age among 20 samples. The average age was 35.60 years 
(range = 18 - 65 years). The figure shows a normally distributed population and based on 
Kolmogorov-Smirnov test on Table 1, the p value was found to be more than 0.05. 
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3.2.2 GENDER  
 
 
 
 
 
 
Figure 2 Gender Distribution of subjects 
 
The figure above shows the gender distribution for this study, male accounted for 50% 
(n=10) and female amounted the same 50% (n=10). 
 
 
 
 
 
 
 
 
 
 
 
50 %(n=10)
50 %(n=10
Gender
male female 
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3.2.3 ETHNICITY  
 
 
 
 
 Figure 3 Distribution of Ethnicity among schizophrenia Subjects 
 
There was equal distribution between Chinese and Indian 35% (n=7) respectively and 
Malays constitute the smallest number, 30% (n=6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
30% (n=6)
35%(n=7)
35%(n=7)
Malay
Chinese
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3.2.4 MARITAL STATUS  
 
 
 
 
  Figure 4 Marital Status of schizophrenia Subjects 
 
Majority of patients were single and accounted at 80% (n=16), followed by divorced 15% 
(n=3) and only 5% (n=1) is married. 
 
 
 
 
 
 
 
 
 
 
 
 
80%(n=16)
5%(n=1)
15%(n=3)
Single
Married
Divorced
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3.2.5 EDUCATIONAL LEVEL  
 
 
 
Figure 5 Education Status of schizophrenia subjects 
 
Based on the bar chart 70 %( 14) of subjects had secondary school education, 20 %( n=4) 
only went to primary school and a small percentage 10 %( 2) had tertiary education. 
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3.2.6. EMPLOYMENT STATUS 
 
 
 
Figure 6 Employment status of schizophrenia subjects  
 
 
A large number of study subjects are unemployed 70% (n=14), 20% (n=4) are employed 
and 10 % (n=2) is either student or housewife. 
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3.2.7 FAMILY HISTORY  
 
 
 
 
         Figure 7: Family History of mental illness among patients 
 
 
The figure above show that 11 patients (55%) has family history of mental illness whereas 
9 (45%) of them do not have any family history of mental illness. 
 
 
 
 
 
 
 
 
 
 
 
55%
45%
Yes
No
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3.2.8 DURATION OF ILLNESS 
 
 
 
   Figure 8: Duration of Illness of Study Subjects 
 
Based on the figure, majority of subjects 35% (n=7) had the illness > 2 years, 20% (n=4) 
had the illness more than 5 years, 15% (n=3) had the illness for 6months to 1 year. 15% 
(n=3) had the illness more than 20 years and more than 10 years respectively. The total 
mean duration of illness is 2.8 years, SD =1.32. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      Duration of illness 
    Duration of illness 
 
    Duration of illness 
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TABLE 2: SUMMARY OF SOCIO-DEMOGRAPHIC CHARACTERISTICS OF 
SCHIZOPHRENIA SUBJECTS 
SOCIO-DEMOGRAHIC 
CHARACTERISTCS  
 
MEAN 
 
SD 
 
n 
 
% 
 
Age 
 
35.60 
 
12.15 
  
Gender 
Male  
Female  
 
 
 
 
 
10 
10 
 
50 
50 
Ethnicity  
Malay  
Chinese 
Indian 
 
 
 
 
 
6 
7 
7 
 
30 
35 
35 
Marital status  
Single  
Divorced 
Married 
 
 
 
 
 
16 
1 
3 
 
80 
15 
5 
Educational level  
Primary  
Secondary  
Tertiary  
 
 
 
 
 
4 
14 
2 
 
20 
70 
10 
Employment  
Employed 
Unemployed 
Student /housewife 
  
 
4 
14 
2 
20 
70 
10 
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TABLE 3: SUMMARY OF SOCIO-DEMOGRAPHIC CHARACTERISTICS OF 
CONTROL SUBJECTS 
SOCIO-DEMOGRAHIC 
CHARACTERISTCS  
 
MEAN 
 
SD 
 
n 
 
% 
 
Age 
 
41.27 
 
8.92 
  
Gender 
Male  
Female  
 
 
 
 
 
8 
7 
 
 
53.3 
46.7 
Ethnicity  
Malay  
Chinese 
Indian 
 
 
 
 
 
7 
6 
2 
 
 
46.7 
40 
13.3 
Marital status  
Single  
Divorced 
Married 
 
 
 
 
 
7 
6 
2 
 
 
46.7 
40 
13.3 
Educational level  
Primary  
Secondary  
Tertiary  
 
 
 
 
 
2 
11 
2 
 
13.3 
73.3 
13.3 
Employment  
Employed 
Unemployed 
Student /housewife 
  
 
 
5 
4 
6 
 
33.33 
26.67 
40 
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3.3 DISTRIBUTION OF CLINICAL DESCRPITIVES 
 
3.3.1 POSITIVE AND NEGATIVE SYNDROME SCALES (PANSS) 
 
 
Figure 9: Distribution of total overall PANSS score in study subjects 
Based on the figure, the total overall mean PANSS score is 85.30, SD =41.92. 
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Figure 10: Distribution of PANSS symptomatology 
PANSS score has been divided into 3 categories low if score less than <75, medium if in 
between ≥75 and < 95 and high if scores equal or more than ≥ 95 (Chris M Kozma 2010). 
From the figure, our study showed that 50% (n=10) had high symptomatology, followed by 
low symptomatology 45% (n=9) and medium symptomatology 5% (n=1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      
Symptomatology 
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3.3.2 BARNES AKATHISIA RATING SCALE  
 
            Figure 11: Distribution of BARS score among study subjects 
The majority of subjects have the total score of 0 which is 85% (n=17) of subjects, 5% have 
the total score of 6 (n=1) and 7 (n=1) and 8 (n=1) respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    TOTAL BARS SCORE 
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3.3.3. NRG 1 GENE EXPRESSION LEVEL IN SCHIZOPHRENIA 
TABLE 4: UNIVARIATE ANALYSIS ASSOCIATION OF DEMOGRAPHIC AND 
CLINICAL FACTORS WITH NRG 1 GENE EXPRESSION LEVEL 
Variable Mean rank P value Z 
Age  
≤35 years  
≥35 years  
 
9.40 
11.60 
 
 
.406 
 
 
-.832 
Gender  
Male 
Female 
 
9.70 
11.30 
 
 
.545 
 
 
-.605 
Ethnicity  
Malay 
Non-Malay 
 
8.83 
11.21 
 
 
.409 
 
 
-.825 
Education 
Primary  
Secondary/Tertiary 
 
12.25 
10.06 
 
 
.508 
 
 
-.661 
Total PANSS 
≤87 
≥87 
 
9.40 
11.60 
 
 
.406 
 
 
-.832 
Total BARS 
≤5 
≥5 
 
10.06 
13.00 
 
 
.427 
 
 
-.794 
Paliperidone 
dosage 
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≤ 6mg 
≥6mg 
8.50 
11.36 
 
3.22 
 
-.990 
Duration on 
Paliperidone 
≤ 6 months 
≥6 months 
 
 
10.50 
10.50 
 
 
1.000 
 
 
 
.000 
 
 
*Mann- Whitney Test 
 
Based on Table 4, NRG 1 gene expression level was compared between above variables as 
to find out any associated factors. There was no significant difference between NRG 1 gene 
expression level with age, gender, ethnicity, education, duration on paliperidone, 
paliperidone dosage, total PANSS and total BARS. 
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TABLE 5: NRG 1 EXPRESSION LEVEL IN SCHIZOPHRENIA PATIENTS AND 
CONTROLS 
 
 
Subjects 
 
NRG 1 gene expression level 
Mean 
 
P value 
PANSS 
Low PANSS score subjects 
Medium PANSS score subjects 
High PANSS score subjects 
 
0.304 
0.118 
0.524 
 
 
0.45 
Schizophrenic subjects  
Control subjects 
0.405 
0.435 
 
0.268 
*Mann- Whitney Test 
 
Based on table 5 , the NRG 1 gene expression level in those with low PANSS score is low, 
mean =0.304 whereas in the high PANSS score group is higher , mean = 0.524. The NRG 1 
level in the high PANSS score group is higher than that of control subject, mean =0.435. 
There is no significant association between NRG 1 level in subjects and NRG 1 level in 
controls. There is no difference between NRG 1 levels in Low PANSS score subjects, 
Medium PANSS score subjects and High PANSS score subjects. 
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TABLE 6: UNIVARIATE ANALYSIS OFASSOCIATED FACTORS WITH 
GENERAL PSYCHOPATHOLOGY (PANSS) OF THE STUDY SUBJECTS  
Variable  Mean rank P Value  Z 
Age  
≤ 35 
≥35 
 
10.95 
10.05 
 
.734 
 
-.340 
 
Gender 
Male  
Female 
 
11.60 
9.40 
.406 -.832 
Ethnicity 
Malay  
Non-Malay 
 
 
9.33 
11.00 
 
.564 
 
-.578 
Education level 
Primary  
Secondary/Tertiary 
 
 
11.50 
10.25 
 
.705 
 
-.378 
Paliperidone dosage 
≤6mg 
≥6mg  
 
10.75 
10.39 
 
.902 
 
-.124 
Duration on 
Paliperidone 
≤6 month 
≥6month 
 
13.38 
9.78 
 
.277 
 
-1.087 
*Mann- Whitney Test 
Based on Table 6, total PANSS score was compared between above variables as to find out 
any associated factors. There was no significant difference between total PANSS score with 
age, gender, ethnicity, education level, duration on paliperidone and paliperidone dosage. 
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TABLE 7: UNIVARIATE ANALYSIS OF ASSOCIATED FACTORS WITH 
POSITIVE SCALE (PANSS) OF THE STUDY SUBJECTS  
Variable  Mean rank P Value  Z 
Age  
< 35 
≥35 
 
10.90 
10.10 
 
.761 
 
-.304 
 
Gender 
Male  
Female 
 
11.90 
9.10 
.287 -1.065 
Ethnicity 
Malay  
Non-Malay 
 
 
8.92 
11.18 
 
.431 
 
-.788 
Education level 
Primary  
Secondary/Tertiary 
 
11.68 
10.16 
 
.601 
 
-.523 
Paliperidone dosage 
≤6mg 
≥6mg  
 
10.50 
10.50 
 
1.000 
 
.000 
Duration on 
Paliperidone 
≤6 month 
≥6month 
 
12.63 
9.97 
 
.419 
 
-.808 
*Mann- Whitney Test 
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Based on Table 7, positive symptoms PANSS score was compared between above variables 
as to find out any associated factors. There was no significant difference between positive 
symptoms PANSS score with age, gender, ethnicity, education level, duration on 
paliperidone and paliperidone dosage. 
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TABLE 8: UNIVARIATE ANALYSIS OF ASSOCIATED FACTORS WITH 
NEGATIVE SCALE (PANSS) OF STUDY SUBJECTS  
Variable  Mean rank P Value  Z 
Age  
≤35 
≥35 
 
11.05 
9.95 
 
.677 
 
-.417 
 
Gender 
Male  
Female 
 
11.60 
9.40 
 
.404 
 
-.834 
Ethnicity 
Malay  
Non-Malay 
 
 
9.42 
10.96 
 
.591 
 
-.538 
Education level 
Primary  
Secondary/Tertiary 
 
 
11.38 
10.28 
 
.740 
 
-.332 
 
 
Paliperidone dosage 
≤6mg 
≥6mg  
 
10.42 
10.54 
 
.967 
 
-.041 
Duration on 
Paliperidone 
≤6 month 
≥6month 
 
 
13.13 
9.84 
 
 
.320 
 
 
-.995 
*Mann- Whitney Test 
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Based on Table 8, negative symptoms PANSS score was compared between above 
variables as to find out any associated factors. There was no significant difference between 
negative symptoms PANSS score with age, gender, ethnicity, education level, duration on 
paliperidone and paliperidone dosage. 
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TABLE 9: UNIVARIATE ANALYSIS OF ASSOCIATED FACTORS WITH 
BARNES AKATHISIA RATING SCALE SCORE OF STUDY SUBJECTS 
Variable  Mean rank P Value  Z 
Age  
≤35 
≥35 
 
10.90 
10.10 
 
.627 
 
-.486 
Gender 
Male  
Female 
 
12.00 
9.00 
 
.068 
 
-1.824 
Paliperidone dosage 
≤6mg 
≥6mg  
 
10.67 
10.43 
 
 
.894 
 
 
-.133 
Duration on 
Paliperidone 
≤6 month 
≥6month 
 
 
9.00 
10.88 
 
 
.362 
 
 
-.912 
*Mann- Whitney Test 
Based on Table 8, total BARS score was compared between above variables as to find out 
any associated factors. There was no significant difference between total BARS score with 
age, gender, duration on paliperidone and paliperidone dosage. 
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TABLE 10: SUMMARY OF CLINICAL DESCRIPTIVES 
 
PANSS 
 
MEAN 
 
SD 
 
n 
 
% 
Positive symptoms 21.95 11.05   
Negative symptoms 22.15 10.36   
General 
psychopathology 
41.20 20.86   
Total PANSS 85.30 41.93   
BARS      
Objective  
Assessment 
.30 .733   
Subjective 
Awareness of 
restlessness 
Distress related to 
restlessness 
 
0.25 
 
.20 
 
.639 
 
.523 
  
Clinical assessment  
of akathisia 
.30 .733   
Total BARS 1.05 2.59   
 
Paliperidone dose  
   
6 
 
30 
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3mg 
6mg 
9mg 
10 
4 
50 
20 
Duration on 
treatment 
≥ 4 weeks  
≥ 8 weeks  
≥24 weeks  
   
4 
4 
12 
 
 
20 
20 
60 
NRG 1 levels  
NRG 1 levels in 
subjects 
NRG 1 levels in 
control 
 
.405 
 
.435 
 
.491 
 
.273 
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CHAPTER 4: DISCUSSION 
 
4.1 METHODOLOGY ISSUES  
While doing this study several hurdles were encountered. This study started out as a 
prospective study as this design is most suited for genetic research. Initiating treatment and 
assessing their baseline symptoms and later on at end of study will give a more accurate 
picture of efficacy of treatment and response to treatment. The gene analysis would also be 
more accurate if able to recruit antipsychotic naïve patients as the sample would not have 
been tainted by previous antipsychotics treatment.  
 
4.2 SAMPLE DESCRIPTION  
4.2.1 AGE AND GENDER 
There were 10 males patients (50%) and 10 females patients (50%). The mean age for our 
study subjects was 35.60 and subjects age ranged from 18 to 65 years old. For 
categorization of age based on gender, the mean age for female subjects were 40.20 years 
(SD= 12.56) and for male subjects mean age is 31.0 years (SD=10.22). This finding is in 
keeping with other studies that showed mean age of onset is younger age of males 49.4 
years (SD=13.1)) and older in female subjects 50.0 years (SD=12.7).Furthermore , those 
with family history the age of onset is younger (Jimmy Lee 2011). 
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4.2.2 MARITAL STATUS  
Our study found that majority of the patients were single 80% (n=16) and they were staying 
with their family or at the nursing home. The relationship between marital status and 
schizophrenia works both ways. That is those who are single are prone to developing 
schizophrenia and those diagnosed to have Schizophrenia are more likely to remain ingle 
(Agerbo, Byrne et al. 2004). This is also found in earlier studies that showed marital status 
as one of the strongest correlate of mental disorder risk. Individuals who were separated or 
divorced had twice the risk compared to those married (Regier, Farmer et al. 1993). 
 
4.2.3 EMPLOYMENT STATUS  
Schizophrenia impairs an individuals‘ cognitive functioning, this may hinder a person 
ability and chance of being employed. In this study 70% (n=14) were unemployed and this 
findings replicates other study findings. There are barriers to gaining employment in those 
with mental illness, among the factors that lessens their chances are stigma from employers, 
negative attitude of employers and community, patients own attitude towards work and 
limited job openings that suits patients ability (unskilled and undemanding job). In a study 
comparing the employment rate between 3 countries United Kingdom (UK), France and 
Germany, the employment rate was lowest in France 11.5%(n=288) compared to UK 
12.5% (n=302) and 30.3%( n=618) Germany .However , the difference in employment rate 
is also attributed to social and service factors that varies between countries (Marwaha, 
Johnson et al. 2007). 
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4.2.4 FAMILY HISTORY  
From the 20 subjects, 55% of the patients have family history of mental illness and 45% of 
them did not have any family history. In the field of genetics family history plays an 
important role as evident in several studies. A study done in Han Chinese schizophrenic 
family trios, suggested that NRG 1 polymorphism could possibly be a pathogenic mutation 
for schizophrenia in Chinese as the transmission disequilibrium test analysis for an NRG1 
variant (rs3924999) showed a signiﬁcant difference between the two transmitted alleles 
(Yang, Si et al. 2003). In contrast, a study done in Han Chinese in Taiwan gave conflicting 
results. The family-based association study (15 schizophrenic bios and 221 schizophrenic 
trios) , 38Gln was transmitted in excess by the parent to the affected offspring whereas the 
case –control association study showed no significant difference in genotype frequency 
between the schizophrenia and normal control (Hong, Huo et al. 2004). 
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4.3 DISTRIBUTION OF CLINICAL DESCRIPTIVES OF THE STUDY 
4.3.1 Distribution mean dose of paliperidone and duration of treatment 
The study showed that the dosage of paliperidone varied between 3mg to 9mg per day and 
the majority of patients dosage was 6mg ,50% (n=10) and 60% (n=12) of the patients had 
been on treatment for 6 months or more. Randomized placebo controlled study using fixed 
doses of oral Paliperidone at 6mg, 9mg and 12 mg respectively showed that all 3 doses of 
Paliperidone ER had broader spectrum of efficacy than placebo. Its capability of rapidly 
improving the acute symptoms of Schizophrenia is due to its rapid onset of action Day 4  
from the first observation point  for those on 12 mg dose and from Day 8 for those on 
Paliperidone ER 6 mg and 9 mg(J. Kane  and P. Lim 2007).  
In another 6-week, randomized,placebo-controlled study demonstrate that patients‘ 
presenting with acute episode of schizophrenia on Paliperidone ER (3 mg, 9 mg and 15 mg 
improved significantly than placebo group.  The improvement in total PANSS score is 
statistically significant (M. Davidson  and P. Lim 2007).  
Schizophrenia is an illness that plagues an individual through his/her life and in this study, 
60% (n=12) of the patients had been on treatment for 6 months or more and majority had 
the illness for more than 2 years 35% (n=7). 15 %( n=3) had the illness more than 10 years 
and 20 years respectively. Paliperidone has also been found to be effective to treat chronic 
schizophrenia , in 3 open label 52 weeks extension studies , long term treatment with 
paliperidone ER is found to be effective in improving patient functioning , improving and 
maintaining symptom control . The dose range for paliperidone ER is between 3 mg ,6mg 
,9mg ,12mg or 15mg administered once daily with favourable metabolic profile and no 
unexpected treatment emergent adverse effects.(Emsley, Berwaerts et al. 2008). Based on 
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the mentioned studies there is no definite dose range of paliperidone ER for schizophrenia 
treatment. 
 
4.3.2 POSITIVE AND NEGATIVE SYNDROME SCALES (PANSS). 
A study done in UMMC , 2009 among 150 patients attending outpatient psychiatry clinic 
found no significant differences in positive, negative and general psychopathology in both  
genders. The mean total score of PANSS was 46.5 in the females and 48.2 in the males 
(Zuraida 2009). Among our study subjects 50% (n=10) had high symptomatology, followed 
by low symptomatology 45% (n=9) and medium symptomatology 5% (n=1). This was 
based on a study done by Kozma et al, the PANSS score was divided into 3 categories low 
if score less than <75, medium if in between ≥75 and < 95 and high if scores equal or more 
than ≥ 95 (Chris M Kozma 2010). Since this was a cross sectional study unable to assess if 
the patients had any response, a PANSS score reduction of 20%-50% from baseline would 
suggest response and patient is seen at least 4 times for assessment (Stefan Leucht and Eva 
Etschel 2005). 
The total mean positive symptoms score is 21.95, total mean negative symptoms score is 
22.95,total mean general psychopathology is 41.20 and total overall means PANSS is 
85.30. The total PANSS score, total positive symptoms score and total negative symptoms 
score were compared between selected variables as to find out any associated factors. There 
were no significant difference between total PANSS score, total positive symptoms score 
and total negative symptoms score with age, gender, ethnicity, education level, duration on 
paliperidone and paliperidone dosage.  
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4.3.3 BARNES AKATHISIA RATING SCALE (BARS) 
Antipsychotics are effective in treating psychosis inpatients however be it typical or 
atypical they have side effects that influences tolerability of the drug. paliperidone ER 
documented side effects includes the commonly reported adverse events are headache, 
agitation, anxiety and insomnia at 12%, 8% and 4% respectively. Incidence of 
extrapyramidal symptoms (EPS) due to paliperidone ER includes akathisia,parkinsonism 
and dystonia, The EPS rate for paliperidone 6 mg (10.2%) appear to be slightly lower than 
for usually therapeutic dosages of risperidone. In a 6 week placebo-controlled trial with 
patients‘ on paliperidone ER treatment, BARS was used to assess akathisia. The findings 
showed that akathisia was rated as absent in 92%–93% of patients in the paliperidone ER 6 
mg and placebo groups, in 90% of the paliperidone ER 9 mg group, and in 87% of the 
paliperidone ER 12 mg group (J. Kane  and P. Lim 2007). In this study BARS was used to 
assess drug induced akathisia, the total score of 0 which is 85% of subjects, 5 % have the 
total score of 6 (n=1) and 7 (n=1) and 8 (n=1) respectively. This indicates that paliperidone 
has a good safety profile and tolerable to patients. 
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4.3.4 NRG 1 GENE EXPRESSION LEVELS IN SCHIZOPHRENIA AND 
ASSOCIATED FACTORS 
From this study it showed there was no significant difference between NRG 1 gene 
expression level with age, gender, ethnicity, education, paliperidone dosage and duration on 
paliperidone. What are the factors that influence the gene expression of NRG 1 expression 
in individuals? Based on the stress diathesis model , interaction between psychosocial and 
preponderance of biological vulnerability can lead to manifestation Schizophrenia (Elaine 
F. Walker 1997). Studies have shown that schizophrenia is heavily influenced by a genetic 
component, unlike RNA and protein, the DNA primary genomic sequence is unaffected by 
external factors. However, we do have to remember that schizophrenia is a multifactorial 
and complex illness. 
Next what is the function of this gene and the role it plays in Schizophrenia? NRG 1 is held 
responsible for regulation of NMDA , GABA and nicotinic receptors, it regulates 
myelination ,neural –glial signaling ,glial development and differentiation ,synapse 
formation and modulate synaptic transmission, neuronal migration and specification and 
transcriptional regulation (Harrison and Law 2006). The fact that it can regulate the 
NMDA, GABA receptors enhances their role as susceptibility gene for Schizophrenia. 
Besides the classic Dopamine hypothesis for schizophrenia other hypothesis such as 
glutamate hypo function at NMDA receptors can produce psychotic symptoms or hyper 
function at non-NMDA receptors (AMPA and kainate) can also produce psychotic 
symptoms (Tsapakis and Travis 2002). 
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There is evidence that NRG 1 regulates NMDA receptor function in the mature brain , NRG 
1 is able to decreased NMDA receptor-mediated currents and channel activity in cortical 
pyramidal neurons by increasing receptor internalization (Gu, Jiang et al. 
2005).Furthermore, the core HAPICE risk haplotype identified in the Icelandic population is 
associated with Bipolar Disorder based on a case-control study and exerts an effect on 
subjects causing cases of psychosis with manic or mood incongruent features. In another 
population, there is association of NRG1 haplotypes in cases of psychosis with preservation 
of affect and a fairly good prognosis (Green EK, Grozeva D et al. 2005) 
Other factors that could have affected NRG 1 gene expression is its interaction with other 
genes or the involvement of multiple genes in Schizophrenia. There is preliminary evidence 
that interactions between several susceptibility genes could alter their individual effect to 
the risk of schizophrenia. There is direct evidence of gene-gene interaction; this was 
detected for NRG1-NRG2, NRG1-NRG3 and EGFR-NRG2, and for ERBB4-NRG1, 
ERBB4-NRG2, ERBB4-NRG3 and ERBB4-ERBB2 suggestive evidence was seen. Genetic 
interaction among these loci may increase susceptibility to schizophrenia (Isabel Benzel, 
Peter R Maycox et al. 2007). 
There is no significant difference between NRG 1 gene expression and the duration on 
paliperidone or with paliperidone dosage. The study of NRG 1 expression in tissue or 
peripheral system has been inconsistent. There are significantly increased expression levels 
of NRG1 transcript variants in type I and type III isoforms in peripheral blood lymphocytes 
in patients with Schizophrenia. However , it was reported that decreased NRG 1 expression 
levels in Schizophrenia based on another study conducted in Han Chinese .The NRG 1 
expression levels significantly increased after treatment with risperidone and quetiapine for 
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2 weeks compared to levels prior to treatment (Hong-Xing Zhang  and Xuan Ouyanga 
2008). Despite this inconsistency, there is evidence supporting that N-methyl-D-aspartate 
(NMDA) receptor hypofunction can be associated with increased signaling and expression 
of NRG1–ErbB4(Hahn, Wang et al. 2006). One of the replicated findings is the effect 
clozapine has on NRG 1 level. In a study using in vitro human fetal brain showed that after 
exposure to clozapine for 3 weeks there was increased expression for NRG 1 (Gursharan 
Chana 2009). In a study using animal tissue clozapine reversed the increased activity of the 
NRG1 TMc-mutant mice in the novel open-field test and T-maze test (Stefansson, 
Sigurdsson et al. 2002). In a Finnish study, patients‘ were divided into responders and non 
responders whereby non responders were given clozapine as treatment. SNP8NRG221533 
was used as the genetic marker and showed that TT genotype was overrepresented in the 
non-responders group compared with the responders. All of this support that NRG 1 
expression levels can be affected by antipsychotic regardless of duration, however it is still 
inconclusive the importance of NRG 1 genotype to treatment of Schizophrenia (Olli 
Kampman and Esa Leinonen 2004). 
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4.3.5. LIMITATIONS AND RECOMMENDATIONS  
This was a preliminary study with several limitations: 
1. This study was under powered because of the small sample size. They are several 
reasons the sample size is small: the initial study started out as a prospective study 
however had to be converted to a cross sectional study. It was unfortunate that 
several blood samples the RNA was damaged hence could not be analyzed. Another 
factor is that, this study involved only one centre which was University Malaya 
Medical Centre which contributed to small sample size. 
2. In this cross sectional study, clinical effect or response of paliperidone could not be 
assessed. In addition, to recruit antipsychotics naive patients that fulfill the inclusion 
criteria were difficult as this is a tertiary centre and most of them were referred here. 
Ideally, further prospective study should be done so that potential influences such as 
clinical response and effect can be found in the future. It would be best that a 
prospective study is carried out to get a more accurate picture of gene expression 
and genotyping. 
3. This study only investigates the gene expression and not genotyping it would be 
good to strengthen findings by doing genotyping. 
4. Furthermore, it was difficult to obtain antipsychotic naïve patients and finding those 
on paliperidone. There were some studies that also look at clozapine effect on NRG 
1, since in UMMC we have a specific clozapine clinic. It will be more feasible to 
recruit patients for a study from this group as there is a ready sample. It would be a 
good measure to recruit patients who is on other types of antipsychotics, perhaps  
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comparing NRG1 expression between 2 groups of patients on different 
antipsychotics. 
5. The lack of serum drug monitoring to monitor patients compliance to treatment was 
another limitation. Compliance to medication could affect the clinical response and 
effect on the genes hence affecting the study outcome. In the future study, the drug 
level monitoring should be made available in order to detect non compliant patients 
and exclude them from the study.  
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CHAPTER 5: CONCLUSION 
 
1. The mean NRG 1 gene expression level in our 20 schizophrenic patients were: mean = 
0.405 and SD = 0.491 and the mean NRG 1 gene expression level in our 15 control 
patients were: mean =0.435 and SD = 0.273. 
 
2. There was no significant association between the age, gender, ethnicity, education, 
dosage of paliperidone, duration on paliperidone and NRG 1 gene expression level. 
 
3. There was no significant correlation between NRG 1 gene expression level and 
psychopathology. 
 
4. Those with low PANSS score had lower NRG 1 levels (mean =0.304) compared to high 
PANSS score (mean = 0.524). 
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IMPLICATIONS 
 
This study would help to highlight the necessity for more research in this field especially in 
a Malaysian setting. This research would help personalized treatment and spare patients 
from going through multiple antipsychotics and expose them to unnecessary side effects. 
This study would hopefully help us to come up with an exclusive Malaysian database that 
caters to our multiracial population. 
This was a cross-sectional study whereby clinical effect or response cannot be assessed. In 
addition to that, a prospective study assessing clinical response would be of beneficial help 
in relation to NRG 1 expression and to investigate NRG 1 genotyping in a multiracial 
population. Hopefully in the future, by determining the levels of NRG1 expression in the 
different races, we can determine which antipsychotics treatment to dispense to our 
patients. 
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APPENDICES 
APPENDIX A 
Patient Information Form 
Patient’s details 
1. Patient‘s name:______________________________________________ 
 
2. R/N                     :_____________________________________________ 
 
3. IC number: ……………………………………………………… 
 
4. Age                      :__________ years 
 
5. Sex                      :  (  ) Male       (  ) Female 
 
6. Race                    :  (  ) Malay     (  ) Chinese    (  ) Indian 
 
7. Marital Status   :     (   ) Single    (   ) Married (    ) divorced 
 
8. Employment Status:  (   ) Employed   (   ) Unemployed  (   ) student/housewife  
 
9. Duration of illness   …………………………………………………….. 
 
10. Family history of mental illness (    ) Yes       (     ) No  
 
11. Duration on Paliperidone treatment ………………………………………………….. 
 
12. Current paliperidone dosage ……………………………………………………… 
 
13. Side effects due to current treatment ………………………………………………….. 
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Parent/guardian detail  
Parent/guardian name :……………………………… 
Age:…………………………………. 
IC number :………………………………… 
Occupation :………………………………………….. 
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APPENDIX  B     UNIVERSITY MALAYA MEDICAL CENTRE 
CONSENT BY PATIENT FOR CLINICAL RESEARCH   
FPU-DOF-BK-012-05-R01
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APPENDIX C 
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APPENDIX D 
 
Name:________________________________________ 
Date:__________________ 
 
Barnes Akathisia Rating Scale (BARS) 
 
Instructions: Patient should be observed while they are seated, and then standing 
while engaged in neutral conversation (for a minimum of two minutes in each 
position). Symptoms observed in other situations, for example while engaged in 
activity on the ward, may also be rated. Subsequently, the subjective phenomena 
should be elicited by direct questioning. 
 
Objective 
0 Normal, occasional fidgety movements of the limbs 
1 Presence of characteristic restless movements: shuffling or tramping movements 
of the legs/feet, or swinging of one leg while sitting, and/or rocking from foot to foot 
or “walking on the spot” when standing, but movements present for less than half 
the time observed 
2 Observed phenomena, as described in (1) above, which are present for at least 
half the observation period 
3 Patient is constantly engaged in characteristic restless movements, and/or has 
the inability to remain seated or standing without walking or pacing, during the time 
observed 
 
Subjective 
Awareness of restlessness 
0 Absence of inner restlessness 
1 Non-specific sense of inner restlessness 
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2 The patient is aware of an inability to keep the legs still, or a desire to move the 
legs, and/or complains of inner restlessness aggravated specifically by being 
required to stand still 
 
3 Awareness of intense compulsion to move most of the time and/or reports strong 
desire to walk or pace most of the time 
 
Distress related to restlessness 
0 No distress 
1 Mild 
2 Moderate 
3 Severe 
 
Global Clinical Assessment of Akathisia 
0 Absent. No evidence of awareness of restlessness. Observation of characteristic 
movements of akathisia in the absence of a subjective report of inner restlessness 
or compulsive desire to move the legs should be classified as pseudoakathisia 
1 Questionable. Non-specific inner tension and fidgety movements 
2 Mild akathisia. Awareness of restlessness in the legs and/or inner restlessness 
worse when required to stand still. Fidgety movements present, but characteristic 
restless movements of akathisia not necessarily observed. Condition causes little 
or no distress. 
3 Moderate akathisia. Awareness of restlessness as described for mild akathisia 
above, combined with characteristic restless movements such as rocking from foot 
to foot when standing. Patient finds the condition distressing 
4 Marked akathisia. Subjective experience of restlessness includes a compulsive 
desire to walk or pace.However, the patient is able to remain seated for at least five 
minutes. The condition is obviously distressing. 
5 Severe akathisia. The patient reports a strong compulsion to pace up and down 
most of the time. Unable to sit or lie down for more than a few minutes. Constant 
restlessness which is associated with intense distress and insomnia. 
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Scoring the Barnes Akathisia Rating Scale (BARS) 
The Barnes Akathisia Rating Scale is scored as follows: 
Objective Akathisia, Subjective Awareness of Restlessness and Subjective 
Distress Related to Restlessness are rated on a 4-point scale from 0 – 3 and are 
summed yielding a total score ranging from 0 to 9. The Global Clinical Assessment 
of Akathisia uses a 5-point scale ranging from 0 – 4. 
 
